Care homes in England are being “failed” by a flawed rollout of rapid-result tests, an expert has warned as analysis of a pilot found “poor” adherence and no impact on outbreaks.
The majority of staff in 11 Liverpool care homes carried out less than a third of the rapid-result lateral flow device (LFD) tests required over six weeks between December and January, according to a pre-print paper.
Researchers from the universities of Liverpool, Nottingham and Imperial College London found no significant difference in the proportion of care homes with outbreaks or the size of outbreaks when comparing the results with homes that were not participating in the pilot.
Traders Magazine
Professor George Skiadopoulos, Queen Mary University of London and University of Piraeus
A common finding when it comes to options trading is that selling index put option contracts (such as those written on the S&P 500) tends to offer average returns and Sharpe ratios which seem to be excessive when compared to equities.
Academic literature has well documented that selling index put options yields high average returns. This is also well known among practitioners: these trades have been highly profitable, except in instances where sales coincide with spikes in volatility, such as when Lehman Brothers crashed, or in the initial heat of the pandemic in March 2020.
Care homes in England are being “failed” by a flawed rollout of rapid-result tests, an expert has warned as analysis of a pilot found “poor” adherence and no impact on outbreaks.
The majority of staff in 11 Liverpool care homes carried out less than a third of the rapid-result lateral flow device (LFD) tests required over six weeks between December and January, according to a pre-print paper.
Researchers from the universities of Liverpool, Nottingham and Imperial College London found no significant difference in the proportion of care homes with outbreaks or the size of outbreaks when comparing the results with homes that were not participating in the pilot.
E-Mail
Being constantly hungry, no matter how much you eat - that s the daily struggle of people with genetic defects in the brain s appetite controls, and it often ends in severe obesity. In a study published in
Science on April 15, researchers at the Weizmann Institute of Science, together with colleagues from the Queen Mary University of London and the Hebrew University of Jerusalem, have revealed the mechanism of action of the master switch for hunger in the brain: the melanocortin receptor 4, or MC4 receptor for short. They have also clarified how this switch is activated by setmelanotide (Imcivree), a drug recently approved for the treatment of severe obesity caused by certain genetic changes. These findings shed new light on the way hunger is regulated and may help develop improved anti-obesity medications.